| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Oncology | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Allogene Therapeutics, Inc.$2
-0.1 (-4.75%)
C 42Pipeline Score Fair Value Biotech · Commercial
Market Cap
707.57 M
EPS
-0.77
P/E Ratio
-2.67 $
Value Trade
18.06 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
32.00 M
Operating CF
-12.91 M
Total Assets
395.96 M
Total Liabilities
117.08 M
Equity
278.88 M
D/E Ratio
12,345
-5.66 %
Week
-14.89 %
1 Month
-6.1 %
3 Month
63.93 %
6 Month
-92.55 %
5 Year
-90.91 %
All Time
Cash Data
Cash Position
266.89 M
Monthly Burn
4.30 M
Runway
60.3 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
7.78 M
52 Week Range
0.98 - 4.46
% held by Insiders
24.6 %
% held by Institutions
39.32 %
Enterprise Value
521.73 M
Total Shares
244.89 M
Short %
37.3 %
Float Shares
169.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Allogene Therapeutics, Inc.
221Total events
8Upcoming
36Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 8
Event history 213
Jun 30, 2026
◆Management ChangeCorporate
David Chang to transition from CEO effective June 30, 2026; Zachary Roberts appointed CEO effective July 1, 2026
Jun 2026
◆Topline ReadoutALLO-329Clinical Data
Initial data from first dosing cohort of RESOLUTION trial for ALLO-329
autoimmune diseases (SLE, lupus nephritis, scleroderma, inflammatory myositis)source ↗
Jun 2026
◆Enrollment Milestonecemacabtagene ansegedleucelTrial
Lymphodepletion selection and futility analysis shifted to 1H 2026
Large B-Cell Lymphomasource ↗
Apr 21, 2026
●Oral PresentationPresentation
Major Symposium: Off-the-Shelf Cell Therapies for Cancer and Beyond by David Chang
Apr 21, 2026
▲IND Clearancecemacabtagene ansegedleucelIND
Regulatory clearance in South Korea and Australia to expand ALPHA3 trial
large B-cell lymphomasource ↗
Apr 21, 2026
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis results from first 24 patients announced
large B-cell lymphomasource ↗
Apr 20, 2026
●Poster PresentationCD70Presentation
Poster: Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma
High-Risk Multiple Myelomasource ↗
Apr 16, 2026
Apr 15, 2026
▲PublicationALLO-329Presentation
Nature Communications publication of pre-clinical data for ALLO-329
autoimmune diseasessource ↗
Apr 15, 2026
▲Trial InitiationALLO-329Trial
Phase 1 RESOLUTION dose escalation rheumatology basket trial actively enrolling
autoimmune diseases (SLE, scleroderma, inflammatory myositis)source ↗
Drug Pipeline Intelligence
C42
Pipeline Score $181M
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored0.9x
rNPV / MCap Top 62%
Micro Cap (rank 347 of 911)
Percentile RankAllogene Therapeutics, Inc. carries a moderate pipeline score (42/100), with $452M risk-adjusted pipeline value, led by ALLO-715 in Relapsed/Refractory Multiple Myeloma (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLO-715 Gene therapy | Relapsed/Refractory Multiple Myeloma | Phase 1 | NCT04093596 | 20% | $167M | COMPLETED | 73 | FAST | D (34) | Jan 27, 2025 | ELEVATED_RISK | MEDIUM Jun 13, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Cema-Cel | 1L Large B-cell Lymphoma (LBCL) | Phase 2 | 2026-05-13 | 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation Arm; At Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation Arm Read More | Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update Read More | |
Cema-Cel | 1L Large B-cell Lymphoma (LBCL) | Phase 2 | 2026-05-13 | 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation Arm; At Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation Arm Read More | Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update Read More | |
Cema-Cel | 1L Large B-cell Lymphoma (LBCL) | Phase 2 | 2026-05-13 | 58.3% (7/12) of Patients in the Cema-Cel Arm Achieved Minimal Residual Disease (MRD) Clearance Compared with 16.7% (2/12) in the Observation Arm; At Day 45, ctDNA Levels Decreased by a Median of 97.7% from Baseline in the Cema-Cel Arm Versus a Median Increase of 26.6% in the Observation Arm Read More | Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALLO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALLO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-02-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALLOAllogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced a leadership transition as Dr. David Chang steps down as CEO after eight years, effective June 30, 2026. Zachary Roberts, currently EVP and CMO, will succeed him starting July 1, 2026. The Board praised Chang's contributions and expressed confidence in Roberts' ability to drive innovation in allogeneic CAR T therapies.
Read more →ALLOMay 26, 2026 3:30 PM EDT : TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The article discusses the TD Cowen 7th Annual Oncology Innovation Summit, scheduled for May 26, 2026. It highlights the event's focus on insights related to the ASCO and EHA conferences. The post appears to be a brief announcement without detailed content or analysis.
Read more →ALLO▲ +6%on this newsshared move
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Read more →ALLOAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported positive interim results from its Phase 2 ALPHA3 trial, indicating that 58.3% of patients treated with Cema-Cel achieved minimal residual disease (MRD) clearance. The company also highlighted a favorable safety profile and significant cash reserves following a public offering. The ongoing Phase 1 RESOLUTION trial for ALLO-329 is showing early signs of clinical activity.
Read more →ALLO▲ +6.5%on this news
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics will report its first quarter 2026 financial results and provide a business update on May 13, 2026. A live audio webcast and conference call will follow the announcement. The company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming for reliable and scalable therapies.
Read more →ALLOAllogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics has received regulatory approval to expand its pivotal Phase 2 ALPHA3 trial to South Korea and Australia. This trial evaluates cemacabtagene ansegedleucel (cema-cel) for patients with large B-cell lymphoma. The expansion aims to enhance patient enrollment and leverage established clinical research infrastructures in these countries. Initial results indicate cema-cel's effectiveness in clearing minimal residual disease.
Read more →ALLOAllogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Allogene Therapeutics announced its participation in the AACR Annual Meeting 2026, showcasing advancements in allogeneic CAR T therapies. The presentations emphasize the potential of these therapies to enhance patient access and simplify treatment delivery. The company is also exploring applications in autoimmune diseases, aiming to provide off-the-shelf solutions for various conditions.
Read more →ALLOAllogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Allogene Therapeutics has successfully closed a public offering of 87.5 million shares at $2.00 each, raising $200.4 million. The funds will be used for general corporate purposes, including clinical trial and research expenses. The offering was managed by several financial institutions, indicating strong market interest.
Read more →ALLOAllogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Allogene Therapeutics announced the publication of pre-clinical data for ALLO-329, a dual-targeted CAR T therapy for autoimmune diseases. The study highlights the potential of ALLO-329 to effectively target CD19+ B cells and CD70+ T cells, enhancing CAR T cell persistence and reducing the need for lymphodepletion. The Phase 1 RESOLUTION trial is currently enrolling patients, with initial data expected in June 2026.
Read more →ALLOAllogene Therapeutics Announces Pricing of Public Offering of Common Stock
Allogene Therapeutics announced the pricing of a public offering of 87.5 million shares at $2.00 each, aiming to raise $175 million. The offering is set to close around April 16, 2026, pending customary conditions. Proceeds will support various corporate needs, including clinical trials and R&D. The company has granted underwriters a 30-day option for additional shares.
Read more →ALLO▼ -25.5%on this newsshared move
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
Allogene Therapeutics announced a proposed public offering of $175 million in common stock, with an option for underwriters to purchase an additional $26.25 million. The proceeds will be used for general corporate purposes, including clinical trial and R&D expenses. The offering is subject to market conditions and is facilitated by major financial institutions.
Read more →ALLO▲ +12.5%on this newsshared move
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Allogene Therapeutics has reported positive interim results from its pivotal ALPHA3 trial, showing that 58.3% of patients treated with cemacabtagene ansegedleucel (Cema-Cel) achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm. The treatment demonstrated a rapid reduction in plasma ctDNA levels and was well-tolerated with no serious adverse events. Enrollment for the trial is expected to complete by the end of 2027, with further analyses planned.
Read more →ALLO▼ -6.5%on this news· ran to -25% by day 3shared move
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Allogene Therapeutics will announce the interim futility analysis data from its pivotal Phase 2 ALPHA3 trial involving cemacabtagene ansegedleucel (Cema-Cel) for first-line consolidation in large B-cell lymphoma. The conference call and webcast are scheduled for April 13, 2026, at 5:30 a.m. PT. This analysis is a significant step in evaluating the therapy's effectiveness.
Read more →ALLOAllogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Allogene Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements in its clinical trials. The company is approaching interim data from the ALPHA3 trial of cema-cel, which aims to prevent relapse in large B-cell lymphoma. Additionally, ALLO-329 is being developed for autoimmune diseases, showcasing innovative CAR T technology. Allogene's financial position remains strong with a cash runway extending into 2028.
Read more →ALLOAllogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Allogene Therapeutics will report its fourth quarter and full year 2025 financial results on March 12, 2026. Following the announcement, a live audio webcast and conference call will be held. The company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming for scalable and readily available therapies.
Read more →ALLO▲ +14.8%on this news
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
Allogene Therapeutics has declared 2026 a pivotal year for its allogeneic CAR T programs, with several key clinical readouts anticipated. The company aims to demonstrate the feasibility of delivering CAR T therapies at biologic-like scale in real-world settings. Their lead program, cema-cel, is currently in a pivotal Phase 2 trial targeting large B-cell lymphoma, while ALLO-329 is exploring applications in autoimmune diseases. Initial data from these trials are expected in the first half of 2026.
Read more →ALLOAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Allogene Therapeutics announced a favorable arbitration outcome for Servier in its dispute with Cellectis, securing full control of the cema-cel product in key markets. This resolution enhances Allogene's position as it approaches critical milestones in the allogeneic CAR T field, including an upcoming interim futility analysis. The company is optimistic about its future prospects despite ongoing clinical and regulatory risks.
Read more →ALLO▲ +12.4%on this newsshared move
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
Allogene Therapeutics reported its Q3 2025 financial results, highlighting advancements in its allogeneic CAR T therapies. The company is pioneering treatments for cancer and autoimmune diseases, with ongoing pivotal trials such as the ALPHA3 trial for LBCL. Financially, Allogene anticipates a cash runway into late 2027, despite expected operating losses.
Read more →ALLOAllogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
Allogene Therapeutics announced a Trial-in-Progress poster presentation for its pivotal Phase 2 ALPHA3 trial at the ASH Annual Meeting. The trial evaluates cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma patients with minimal residual disease after standard treatment. This innovative therapy aims to provide immediate treatment options, positioning Allogene at the forefront of CAR T therapy advancements.
Read more →ALLOAllogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
Read more →ALLOAllogene Therapeutics Announces Participation in Upcoming Investor Conference
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation in Large B-Cell Lymphoma (
Allogene Therapeutics reported its financial results for Q2 2025, showcasing strong advancements in their clinical trials, particularly the ALPHA3 trial for Cemacabtagene Ansegedleucel (Cema-Cel) in large B-cell lymphoma. The trial is proceeding as a two-arm randomized study, with preliminary data showing favorable safety and efficacy indicators. Additionally, the company has a solid cash position of $302.6 million, which is expected to support operations through the second half of 2027.
Read more →ALLO▼ -5.4%on this news
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Read more →ALLO▼ -12.2%on this newsshared move
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Allogene Therapeutics has chosen standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in treating large B-cell lymphoma. This decision follows a serious adverse event in a related trial arm. The amended trial aims to compare cema-cel after FC lymphodepletion to observation, with the next milestone expected in early 2026.
Read more →ALLO▲ +8.5%on this news
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Allogene Therapeutics presented updated Phase 1 data for ALLO-316 at the 2025 ASCO Annual Meeting, highlighting its effectiveness in advanced renal cell carcinoma. The trial demonstrated a 31% overall response rate among patients previously resistant to therapies. ALLO-316's safety profile was manageable, with no severe adverse events reported. These findings suggest significant potential for durable responses and long-term disease control.
Read more →ALLOAllogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
Read more →ALLOAllogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation in Large B-Cell Lymphoma (L
Allogene Therapeutics reported its first-quarter financial results for 2025, highlighting significant updates on its clinical trials, especially the pivotal Phase 2 ALPHA3 trial for Cema-Cel in Large B-Cell Lymphoma. With nearly 50 clinical sites activated across the U.S., the trial is seeing strong interest, leading to over 250 patients already consented for MRD screening. However, some timelines have been pushed back, with key analyses now slated for the first half of 2026. The company ended the quarter with $335.5 million in cash, enabling continued investment in its high-priority clinical programs.
Read more →ALLO▼ -21%on this news
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
Read more →ALLOAllogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Read more →ALLOAllogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Read more →ALLO▼ -8.3%on this news
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel) First
Allogene Therapeutics reported its financial results for Q4 and full year 2024, highlighting advancements across its clinical programs. The company focuses on its pivotal Phase 2 trial for cema-cel in large B-cell lymphoma and received FDA clearance for its ALLO-329 trial in autoimmune diseases. Positive early data from the ALLO-316 trial in renal cell carcinoma was also shared. Despite significant financial losses, Allogene maintains a cash runway supporting operations into the second half of 2026.
Read more →ALLO▼ -7.7%on this news
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Read more →ALLOAllogene Therapeutics Announces Participation in March Investor Conference
Allogene Therapeutics Announces Participation in March Investor Conference
Read more →ALLO▼ -7.2%on this newsshared move
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
Read more →ALLOAllogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Read more →ALLOAllogene Therapeutics Announces Participation in February Investor Conferences
Allogene Therapeutics Announces Participation in February Investor Conferences
Read more →ALLOAllogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
Read more →ALLOAllogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Read more →ALLO▲ +9%on this news
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Read more →ALLO▼ -5.6%on this newsshared move
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Read more →ALLOAllogene Therapeutics Announces Participation in December Investor Conferences
Allogene Therapeutics Announces Participation in December Investor Conferences
Read more →ALLO▼ -5.3%on this newsshared move
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Read more →ALLOAllogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Read more →ALLOAllogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update Cemacabtagene Ansegedleucel (Cema-Cel) 1L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Sit
Allogene Therapeutics reported its third quarter 2024 financial results and updates on several clinical trials, including the pivotal Phase 2 ALPHA3 trial for its CAR T cell product, Cema-Cel, in large B-cell lymphoma. The trial shows potential to improve outcomes in high-risk patients, with an enrollment completion expected by 1H 2026 and a BLA submission targeted for 2027. Additionally, ALLO-316's promising Phase 1 results in advanced renal cell carcinoma suggest it may be a viable treatment option. The company continues to maintain a robust cash position projected to sustain operations through mid-2026.
Read more →ALLOAllogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read more →ALLO▲ +10.3%on this newsshared move
Allogene Therapeutics Announces Participation in November Investor Conferences
Allogene Therapeutics Announces Participation in November Investor Conferences
Read more →ALLO▼ -5.7%on this newsshared move
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
Read more →ALLOAllogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Read more →ALLOAllogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Read more →ALLOAllogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update Cemacabtagene Ansegedleucel (Cema-Cel) 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in Ju
Allogene Therapeutics reported encouraging progress in its pivotal Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (Cema-Cel) aimed at treating large B-cell lymphoma. The trial is ahead of schedule with ten sites activated and patient enrollment proceeding as planned, targeting completion by mid-2026. The company also continues to innovate with its ALLO-329 and ALLO-316 programs, anticipating key updates on these trials and financial management amid ongoing operational expenses. Their financial report for Q2 2024 showed a significant cash position but reflected substantial losses.
Read more →ALLOAllogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
Read more →ALLOAllogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Read more →ALLO▲ +9.4%on this news
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Read more →ALLOAllogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
Read more →ALLO▲ +5.1%on this news
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforc
Allogene Therapeutics reported its financial results for Q1 2024, revealing a net loss of $65 million while holding $397.3 million in cash. The company has expanded its CD19 oncology rights to include all EU member states and the UK, increasing the potential market opportunity for its therapy, Cemacabtagene Ansegedleucel (Cema-Cel), to over $9.5 billion. Key ongoing trials, including the pivotal ALPHA3 trial, are expected to keep advancing, with initial results anticipated by the end of 2024. The firm plans to extend its clinical and commercial operations, especially in large B cell lymphoma and chronic lymphocytic leukemia treatments.
Read more →ALLO▲ +5.1%on this news
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
Read more →ALLOAllogene Therapeutics Announces Q2 Investor Conference Participation
Allogene Therapeutics Announces Q2 Investor Conference Participation
Read more →ALLO▼ -7.9%on this news
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) Start-Up Activities Underw
Allogene Therapeutics has reported its fourth quarter and full year 2023 financial results, highlighting ongoing developments in its therapeutic pipeline. The company is implementing the pivotal ALPHA3 trial for cema-cel, targeting large B-cell lymphoma, with activities beginning mid-2024. The company also initiated the Phase 1 ALPHA2 trial for chronic lymphocytic leukemia and is expected to introduce ALLO-329, a next-generation CAR T therapy targeting autoimmune diseases, by early 2025. Despite a significant net loss, Allogene reassures investors of a solid cash runway into 2026.
Read more →ALLOAllogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
Read more →ALLOAllogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Read more →ALLOAllogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
Read more →ALLO▲ +17.8%on this news
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak and Dagger Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak and Dagger Technologies at the Society for Immunotherapy of Cancer Annual Meeting
Read more →ALLOAllogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
Read more →ALLOAllogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T
Allogene Therapeutics provided an update on its third quarter financial results and ongoing clinical trials for its AlloCAR T technologies. The company reported a robust cash position of $497.7 million, expected to support operations through the second half of 2025. Significant progress is being made in its ALPHA2 trial for ALLO-501A targeting relapsed refractory large B cell lymphoma, along with the introduction of next-generation approaches aimed at enhancing CAR T cell engraftment and efficacy. Allogene also announced preclinical validation of ALLO-182, an investigational therapy targeting Claudin18.2 for gastric and pancreatic cancers.
Read more →ALLOAllogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
Read more →ALLOAllogene Therapeutics Appoints Earl Douglas as General Counsel
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed Refractory Large B Cell Lymphoma (LBCL) at the A
Allogene Therapeutics has reported its second-quarter financial results, showcasing the promising long-term data for its allogeneic CD19 CAR T product candidate, ALLO-501A, in relapsed refractory large B cell lymphoma. The company is actively enrolling patients in Phase 2 trials, with expected data readouts by the end of 2024, indicating potential for significant advancements in treatment options. Financially, Allogene ended the quarter with approximately $545 million in cash, but is anticipating a net loss and decreased cash reserves for the year.
Read more →ALLOAllogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
Read more →ALLOAllogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
Read more →ALLOAllogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Read more →ALLO▼ -6%on this news
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
Read more →ALLOAllogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Read more →ALLO▲ +6.9%on this news· ran to +21% by day 1
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update Enrollment Ongoing in Industry's First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed Refractory Large B Cel
Allogene Therapeutics provided its Q1 2023 financial results and business updates, highlighting ongoing enrollment in the pivotal Phase 2 ALPHA2 trial for ALLO-501A, aimed at relapsed refractory large B cell lymphoma. The company also initiated the EXPAND trial to support the licensure of ALLO-647. Financial results showed a net loss of $98.7 million, but a robust cash position of $514 million was reported, projecting a cash runway into Q2 2025. Promising interim data from the ALLO-316 trial indicated early anti-tumor activity in renal cell carcinoma, although there are noted safety concerns associated with the treatment.
Read more →ALLOAllogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Read more →ALLOAllogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
Read more →ALLOAllogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
Read more →ALLOAllogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
Read more →ALLO▲ +10%on this newsshared move
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
Read more →ALLOAllogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Read more →ALLOAllogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
Read more →ALLO▼ -5%on this news
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Read more →ALLOAllogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
Read more →ALLOAllogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Initiated Industry's First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed Refractory
Allogene Therapeutics announced its financial results for Q4 and the full year of 2022, highlighting significant advancements in its allogeneic CAR T therapy pipeline. The company initiated the ALPHA2 Phase 2 trial for ALLO-501A, targeting relapsed refractory large B cell lymphoma. Data showed durable responses similar to existing autologous therapies. The company also reported strong financial results, concluding 2022 with $576 million in cash, positioning itself well for continued developments in its CAR T technology.
Read more →ALLO▼ -7.2%on this news
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
Read more →ALLOAllogene Therapeutics Presents Data on Dagger, a Next Generation AlloCAR T Platform Technology
Allogene Therapeutics Presents Data on Dagger, a Next Generation AlloCAR T Platform Technology
Read more →ALLOAllogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T Target for Small Cell Lung Cancer
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T Target for Small Cell Lung Cancer
Read more →ALLO▲ +15.7%on this newsshared move
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
Read more →ALLOAllogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Read more →ALLO▼ -8.4%on this newsshared move
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
Read more →ALLO▼ -9.3%on this news
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T Platform
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T Platform
Read more →ALLOAllogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R D Showcase Initiated the Industry's First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed Refracto
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R D Showcase Initiated the Industry's First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed Refractory Large B Cell Lymphoma Patients, is Designed to Leverage
Read more →ALLO▼ -5.8%on this news
Allogene Therapeutics Reports Second Quarter 2022 Financial Results U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry's First Allogeneic CAR T Phas
Allogene Therapeutics Reports Second Quarter 2022 Financial Results U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry's First Allogeneic CAR T Phase 2 Pivotal Trial Clearance to Cover ALPHA2 Protocol and
Read more →ALLO▲ +10.2%on this news
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
Read more →ALLOAllogene Therapeutics Reports First Quarter 2022 Financial Results Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projecte
Allogene Therapeutics Reports First Quarter 2022 Financial Results Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of 20,000 Doses of AlloCAR T
Read more →ALLOAllogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR's Annual Meeting and in Cancer Research Journal
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR's Annual Meeting and in Cancer Research Journal
Read more →ALLOAllogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
Read more →ALLO▼ -5.7%on this news
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update AlloCAR T Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update AlloCAR T Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022 Phase 1 Data from the ALPHA Trials in Relapsed Refractor
Read more →ALLO▲ +5.7%on this news
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR Technology
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR Technology
Read more →ALLO▼ -9.4%on this newsshared move
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clinical Trials
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T Clinical Trials
Read more →ALLO▼ -5.2%on this news
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Read more →ALLO▲ +7.5%on this news
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
Read more →ALLO▼ -21.7%on this newsshared move
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Read more →ALLO▼ -21.7%on this newsshared move
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin's Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin's Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Read more →ALLOAllogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Read more →ALLOAllogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Read more →ALLOAllogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T Trials to be Presented at the 63rd Annual Meeting of the American So
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Ora
Read more →ALLOAllogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T Trials at the 63rd Annual Meeting of the American Society of Hematology
Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T Trials at the 63rd Annual Meeting of the American Society of Hematology
Read more →ALLO▲ +7.6%on this news· ran to +23% by day 3
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021
Read more →ALLOAllogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Read more →ALLOAllogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board
Read more →ALLOAllogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Read more →ALLOAllogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2021 Financial Results CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Dur
Allogene Therapeutics Reports Second Quarter 2021 Financial Results CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Ther
Read more →ALLOAllogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Read more →ALLOAllogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
Read more →ALLOAllogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Read more →ALLOAllogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology
Read more →ALLOAllogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021
Read more →ALLOAllogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
Read more →ALLOAllogene Therapeutics Reports First Quarter 2021 Financial Results CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO)
Allogene Therapeutics Reports First Quarter 2021 Financial Results CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Longer Term Follow-Up from the ALPHA Stud
Read more →ALLOAllogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Read more →ALLOAllogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
Read more →ALLOAllogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T Cell Therapy in Development for Relapsed/Refractory Multiple Myeloma
Read more →ALLOAllogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Read more →ALLOAllogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Read more →ALLOAllogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
Read more →ALLOAllogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Provid
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T Therapy in Rel
Read more →ALLOAllogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Read more →ALLOAllogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Read more →ALLOAllogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
Read more →ALLOAllogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Read more →ALLOAllogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Read more →ALLOAllogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T Cell Therapies
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T Cell Therapies
Read more →ALLOAllogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Read more →ALLOAllogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Read more →ALLOAllogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
Read more →ALLOAllogene Therapeutics Reports Third Quarter 2020 Financial Results Enrollment Ongoing in Phase 1 Trials of ALLO-501 (ALPHA), ALLO-501A (ALPHA2) and ALLO-715 (UNIVERSAL) Initial Phase 1 Results from the UNIVERSAL Trial in
Allogene Therapeutics Reports Third Quarter 2020 Financial Results Enrollment Ongoing in Phase 1 Trials of ALLO-501 (ALPHA), ALLO-501A (ALPHA2) and ALLO-715 (UNIVERSAL) Initial Phase 1 Results from the UNIVERSAL Trial in Relapsed Refractory Multiple Myeloma to be Presented at a
Read more →ALLOAllogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T)
Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T)
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2020 Financial Results Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Na
Allogene Therapeutics Reports Second Quarter 2020 Financial Results Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Na ve Relapsed Refractory Non-Hodgkin Lymphoma Patients In t
Read more →ALLOAllogene Therapeutics Announces Commencement of Public Offering of Common Stock
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., June 1, 2020 - Allogene Therapeutics, Inc. (Nasdaq ALLO), today announced the commencement of an underwritten public offering of $450.0 million of shares of its common st
Read more →ALLOAllogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting
Read more →ALLOAmerican Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
Read more →ALLOAllogene Therapeutics Reports First Quarter 2020 Financial Results Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed Refractory Non-Hodgkin Lymphoma at the Virtual American Society of
Allogene Therapeutics Reports First Quarter 2020 Financial Results Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 ALPHA2 Tr
Read more →ALLOAllogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology
Read more →ALLOAllogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in
Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in Relapsed Refractory Multiple Myeloma On-Track for Q2 2020 a
Read more →ALLOAllogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Read more →ALLOAllogene Therapeutics Announces February and March 2020 Investor Conference Schedule
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
Read more →ALLOAllogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Read more →ALLOAllogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Read more →ALLOAllogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
Read more →ALLOAllogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T Pipeline at 61st American Society of Hematology Annual Meeting
Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T Pipeline at 61st American Society of Hematology Annual Meeting
Read more →ALLOAllogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
Read more →ALLOAllogene Therapeutics Reports Third Quarter 2019 Financial Results Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM) Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relap
Allogene Therapeutics Reports Third Quarter 2019 Financial Results South San Francisco, Calif., November 5, 2019 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ) therapies for cancer,
Read more →ALLOAllogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019
Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019
Read more →ALLOAllogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Read more →ALLOAllogene Therapeutics Announces September 2019 Investor Conference Schedule
Allogene Therapeutics Announces September 2019 Investor Conference Schedule
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2019 Financial Results ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Advances with Five Clinical Trial Sites Open Investigationa
Allogene Therapeutics Reports Second Quarter 2019 Financial Results South San Francisco, Calif., August 7, 2019 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ) therapies for cancer,
Read more →ALLOAllogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
Read more →ALLOAllogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
Read more →ALLOAllogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T) Therapy
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T) Therapy
Read more →ALLOAllogene Therapeutics Announces June 2019 Investor Conference Schedule
Allogene Therapeutics Announces June 2019 Investor Conference Schedule
Read more →ALLOAllogene Therapeutics Reports First Quarter 2019 Financial Results Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Investigational New Drug (IND) Application Submitt
Allogene Therapeutics Reports First Quarter 2019 Financial Results South San Francisco, Calif., May 7, 2019 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ) therapies for cancer, today
Read more →ALLOAllogene Therapeutics Announces Expansion of Scientific Advisory Board
Allogene Therapeutics Announces Expansion of Scientific Advisory Board
Read more →ALLOAllogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
Read more →ALLOAllogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715, an Anti-BCMA AlloCAR T Therapy in Multiple Myeloma
Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715, an Anti-BCMA AlloCAR T Therapy in Multiple Myeloma
Read more →ALLOAllogene Therapeutics Announces April 2019 Investor Conference Schedule
Allogene Therapeutics Announces April 2019 Investor Conference Schedule
Read more →ALLOAllogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Read more →ALLOAllogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019 Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-50
Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results South San Francisco, Calif., March 8, 2019 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ) therapies
Read more →ALLOAllogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
Allogene Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 8, 2019
Read more →ALLOAllogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T) Therapies
Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T) Therapies
Read more →ALLOAllogene Therapeutics Announces February and March 2019 Investor Conference Schedule
Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
Read more →ALLOAllogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy
Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy
Read more →ALLOAllogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Allogene Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Read more →ALLOAllogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia
Read more →ALLOAllogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
Read more →ALLOAllogene Therapeutics Announces November 2018 Investor Conference Schedule
Allogene Therapeutics Announces November 2018 Investor Conference Schedule
Read more →ALLOAllogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares South San Francisco, Calif.
Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Francisco, Calif., October 15, 2018 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the devel
Read more →ALLOAllogene Therapeutics Announces Pricing of Initial Public Offering
Allogene Therapeutics Announces Pricing of Initial Public Offering
Read more →ALLOAllogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
Read more →Competitive Position
How ALLO ranks across every disease it competes inCompetitive Position is a premium feature
See how ALLO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial